Methods for diagnosing lung cancer using microRNAs
The present invention provides novel methods and compositions for the diagnosis and treatment of solid cancers. The invention also provides methods of identifying inhibitors of tumorigenesis.
1. A method of diagnosing a subject having lung cancer, comprising:
a.) obtaining a test sample from a subject having, or suspected of having lung cancer, wherein the sample is extracted from lung tissue;
b.) measuring, by hybridization assay, the level of at least three miR gene products in the test sample;
c.) comparing the level of at least one miR-21 gene product, one miR-210 gene product, and one miR-205 gene product in the test sample from the subject to a corresponding control level of at least one miR-21 gene product, one miR-210 gene product, and one miR-205 gene product; and
d.) diagnosing the subject as having lung cancer, if the level of at least one miR-21 gene product, one miR-210 gene product, and one miR-205 gene product in the test sample from the subject is greater than the corresponding control level of miR-21 gene product, miR-210 gene product, and miR-205 gene product;
wherein an increase in the levels of the miR-21 gene product, the miR-210 gene product and the miR-205 gene product, is indicative of the subject having lung cancer.
2. A method of diagnosing a subject having lung cancer, comprising:
a.) obtaining a test sample from a subject having, or suspected of having lung cancer, wherein the sample is extracted from lung tissue;
b.) reverse transcribing at least miR-21 gene product, miR-210 gene product, and miR-205 gene product from the test sample from the subject to provide at least three corresponding miR gene product target oligonucleotides;
c.) hybridizing at least miR-21, miR-210, and miR-205 target oligodeoxynucleotides to a microarray comprising miRNA-specific probe oligonucleotides that include at least one corresponding miR-21, miR-210, and miR-205 RNA-specific probe oligonucleotides to provide a hybridization profile for the test sample;
d.) comparing the test sample hybridization profile to at least one control hybridization profile; and
e.) diagnosing the subject as having lung cancer if the level of at least three corresponding miR gene products in the hybridization profile from the test sample is greater than the control levels of corresponding miR-21 gene product, miR-210 gene product, and miR-205 gene product,
wherein an increase in the levels of the miR-21 gene product, the miR-210 gene product and the miR-205 gene product, is indicative of the subject having lung cancer.